Abstract
An epilogue, according to the dictionary, is “the final part that serves typically to round out or complete the design of a ... work” or provides “an afterword.” The editors thought an epilogue might be more appropriate than a summary of the papers of distinguished colleagues most of whom had, in any event, provided their own summaries or conclusions.
Keywords
Tissue Factor Coagulation Protein Warfarin Plus Thromboplastin Reagent Rabbit Brain Thromboplastin
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1).G. L. Long, R. M. Belagaje and R. T. A. MacGilivray, Cloning and sequencing of liver cDNA coding for bovine protein C. Proc Natl Acad Sci U.S.A. 81:5653 (1984).PubMedCrossRefGoogle Scholar
- 2).L. C. Pan and P. A. Price, The propeptide of rat bone gamma-carboxy-glutamic acid protein shares homology with other vitamin Independent protein precursors. Proc Nat Acad Sci U.S.A. 82:6109 (1985).PubMedCrossRefGoogle Scholar
- 3).J. W. Suttie, J. A. Hoskins, J. Engelke, A. Hopfgartner, H. Ehrlich, N. U. Bang, R. M. Belagaje, B. Schoner, and G. L. Long, Vitamin K-dependent carboxylase: possible role of the “propeptide” as an intracellular recognition site (gamma-carboxyglutamic acid/ protein C), Proc Natl Acad Sci U.S.A. (1987) in press.Google Scholar
- 4).B. A. M. Soute, W. Muller-Esterl, M. A. G. de Boer-van den Berg, M. Ulrich and C. Vermeer, Discovery of a gamma-carboxyglutamic acid-containing protein in human spermatozoa. FEBS 190:137 (1985).CrossRefGoogle Scholar
- 5).A. Faggiotto, R. Ross, L. Harker, Studies of hyperchloresterolemia in the non-human primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 4:323 (1984).PubMedCrossRefGoogle Scholar
- 6).A. Faggiotto, R. Ross, L. Harker, Studies of hyperchloresterolemia in the non-human primate. II. Changes that lead to fatty streak conversion to fibrous plaque. Arteriosclerosis 4:341 (1984).PubMedCrossRefGoogle Scholar
- 7).T. W. Meade, W. R. S. North, R. Chakrabarti, Y. Stirling, A. P. Haines, S. G. Thompson and M. Brozovic, Haemostatic function and cardiovascular death: early results of a prospective study. Lancet I: 1050 (1980).CrossRefGoogle Scholar
- 8).T. W. Meade, Y. Stirling, S. G. Thompson, M. V. Vickers, L. Woolf, A. B. Ajdukiewicz, G. Stewart, J. F. Davidson, I. D. Walker, A. S. Douglas, et al., An International and Interregional comparison of Haemostatic Variables in the study of Ischaemic Heart Disease. Report of a Working Group. Int J Epidemiology 15:331 (1986).CrossRefGoogle Scholar
- 9).M. Zur, R. D. Radcliffe, J. Oberdick and Y. Nemerson, The dual role of factor VII in coagulation: initiation of coagulation by a zymogen. J Biol Chem 257:5623 (1982).PubMedGoogle Scholar
- 10).U. Seligsohn, C. K. Kasper, B. Osterud, S. I. Rapaport, Activated Factor VII: Presence in Factor IX concentrates and persistance in the circulation after infusion. Blood 53:828 (1979).PubMedGoogle Scholar
- 11).V. Hedner and W. Kisiel, Use of human factor VIIa in treatment of two haemophiliac A patients with high titer inhibitors. J Clin Invest 71:1836 (1983).PubMedCrossRefGoogle Scholar
- 12).G. J. Miller, S. J. Walter, Y. Stirling, S. G. Thompson, M. P. Esnouf, T. W. Meade, Assay of Factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipi-daemia, with possible implications for ischaemic heart disease. Brit J Haematology 59:249 (1985).CrossRefGoogle Scholar
- 13).K. Dalaker, I. Hjermann, H. Prydz, A novel form of Factor VII in plasma for men at risk for cardiovascular disease. Brit J Haematology 61:315 (1985).CrossRefGoogle Scholar
- 14).L. A. Salberg and J. P. Strong, Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis 3:187 (1983).CrossRefGoogle Scholar
- 15).T. Gordon, M. R. Garcia-Palmieri, A. Kagan, W. E. Kannel, and J. Schiffman, Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chronic Dis 27:329 (1974).PubMedCrossRefGoogle Scholar
- 16).J. Stamler and F. H. Epstein, Coronary heart disease: risk factors as guides to preventive action. Prev Med 1:27 (1972).PubMedCrossRefGoogle Scholar
- 17).H. C. McGill, Jr., Risk factors in atherosclerosis. Adv Exp Med Biol 104:273 (1978).PubMedCrossRefGoogle Scholar
- 18).The Framingham Study: an epidemiologic investigation of cardiovascular disease. Monograph sections 26–27. PHEW Publication. National Heart Institute (1970, 71).Google Scholar
- 19).J. Hermans, T. van den Besselaar, E. A. Loeliger, E. A. van der Veide, A collaborative calibration study of reference materials for thromboplastin. Thromb Haemost 50:712 (1983).PubMedGoogle Scholar
- 20).J. A. Koepke and D. A. Triplett, Standardization of the prothrombin time — finally. Arch Path Lab Med 109:800 (1985).PubMedGoogle Scholar
- 21).R. G. Berger and N. N. Hadler, Treatment of calcinosis universalis secondary to dermatomyositis or scleroderma with low dose warfarin. Presented at the annual meeting of the American Rheumatism Association, San Antonio, Texas. June 1–4, 1983.Google Scholar
- 22).M. M. Bern, A. Bothe, Jr., B. Bistrian, C. D. Champagne, M. S. Keane, G. L. Blackburn, Prophylaxis against central vein thrombosis with low-dose warfarin. Surgery 99:216 (1986).PubMedGoogle Scholar
- 23).M. Samama, M. H. Horellou, J. Soria, J. Conrad, G. Nicholas, Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulant treatment. Thromb Haemost 51:132 (1984).PubMedGoogle Scholar
- 24).P. Zauber and M. W. Stark, Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Int Med 104:659 (1986).PubMedCrossRefGoogle Scholar
- 25).H. F. Dvorak, Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Eng J Med 315:1650 (1986).PubMedCrossRefGoogle Scholar
Copyright information
© Springer Science+Business Media New York 1987